中文摘要：

目的探讨可溶性细胞间粘附分子-1（slCAM-1）在慢性乙型肝炎（简称乙肝）、乙肝肝硬化及原发性肝癌患者血清中的表达及其意义。方法选择慢性乙肝及其相关性肝病患者225例为研究对象，按照不同临床类型分为5组：自然痊愈组（66例）、无症状HBV携带组（22例）、慢性乙肝组（65例）、乙肝肝硬化组（失代偿或代偿肝硬化）（28例）和原发性肝癌组（51例）；另选24名健康体检者作为正常对照组，利用ELISA法对5组患者及对照组血清slCAM-1水平进行测定。结果慢性乙肝组血清中slCAM-1水平（910±210） μg／L，明显高于正常对照组（567±107） μg／L（t=4．172，P〈0．01）：原发性肝癌组血清中slCAM-1水平（1179±541） μg／L，明显高于慢性乙肝组（t=3．208，P〈0．01）：乙肝肝硬化组血清中slCAM-1水平（1906±682） μg／L，明显高于原发性肝癌组（t=4．084，P〈0.01）。自然痊愈组血清slCAM-1水平（594±348） μg／L及无症状携带组血清slCAM-1水平（570±181） μg／L与正常对照组比较差异均无统计学意义（P〉0．05）。结论慢性乙肝及乙肝相关性肝病患者slCAM-1的表达均升高，这可作为临床乙肝活动和乙肝相关性肝病损害的指标。

英文摘要：

Objective To investigate the serum levels of slCAM-1 in chronic hepatitis B and HBV-related diseases. Methods Serum samples were collected from 65 cases of chronic hepatitis B, 51 cases of hepatocellular carcinoma （HCC） ,28 cases of cirrhosis, 66 completed recovered patients and 22 asymptomatic HBV carriers. Serum slCAM-1 levels were measured by double antibody sandwich ABC-ELISA. Results The slCAM-1 levels of chronic hepatitis B were significantly higher than those of normal control（ 910 ± 510 μg/L vs 567 ± 107 μg/L, t=4.172, P〈0.01）. The slCAM-1 levels of HCC（ 1179 ± 541 μg/L） were significantly higher than those of chronic hepatitis B （t=3.208, P〈0.01）. The slCAM-1 level of hepatitis B cirrhosis（ 1906 ± 682 μg/L ）were significantly higher than those of HCC（t=4.084, P〈0.01 ）. The slCAM- 1 levels of completely recovered cases （ 594 ± 348 μg/L ）and those of asymptomatic carriers （ 570 ± 181 μg/L ）were not significantly different from those of normal control （P〉0.05）. Conclusion Serum slCAM-1levels are increased significantly in chronic hepatitis B and HBV-related liver diseases, which suggest that serum slCAM-1 can be used as an indicator for severity of chronic hepatitis B and HBV-related liver damage.